<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631305</url>
  </required_header>
  <id_info>
    <org_study_id>HPS-01</org_study_id>
    <nct_id>NCT01631305</nct_id>
  </id_info>
  <brief_title>Levothyroxine for Children With Euthyroid Sick Syndrome</brief_title>
  <official_title>Efficacy and Safety of Levothyroxine in Critical Children With Euthyroid Sick Syndrome in a Pediatric Intensive Care Unit.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinaloa Pediatric Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinaloa Pediatric Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether levothyroxine is effective and safe in the
      treatment of children with euthyroid sick syndrome, hospitalized in a pediatric intensive
      care unit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with euthyroid sick syndrome, hospitalized in a pediatric intensive care unit, will
      be randomised to receive either Levothyroxine or placebo, to determine if it diminishes
      mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of time in intensive care</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation days</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of vasopressors</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid hormones levels</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Euthyroid Sick Syndrome</condition>
  <arm_group>
    <arm_group_label>Levothyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mcg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcium magnesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>3 mcg/kg/day</description>
    <arm_group_label>Levothyroxine</arm_group_label>
    <other_name>Brand: Eutirox.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Calcium magnesia</intervention_name>
    <description>Placebo.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All children aged 1 month to 17 years.

          -  Admitted to pediatric intensive care unit.

          -  TSH and thyroid hormones below age specific levels.

        Exclusion Criteria:

          -  Known thyroid condition.

          -  Brain death.

          -  Gut conditions that contraindicate oral route.

          -  Readmissions to intensive care unit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesus J Martinez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sinaloa Pediatric Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sinaloa Pediatric Hospital</name>
      <address>
        <city>Culiacan</city>
        <state>Sinaloa</state>
        <zip>80200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://hospitalpediatrico.org/</url>
    <description>Sinaloa Pediatric Hospital</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sinaloa Pediatric Hospital</investigator_affiliation>
    <investigator_full_name>Jesús Javier Martínez-García</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Euthyroid Sick Syndromes</keyword>
  <keyword>Thyroxine</keyword>
  <keyword>Intensive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Euthyroid Sick Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

